Companies/4basebio Plc
Follow

4basebio Plc

London AIM (United Kingdom)

4basebio is focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients.
Go to market

Sector:
HEALTH CARE
Media
www.4basebio.com
Current instruments
Type
Ticker
ISIN
SHARE
4BB
GB00BMCLYF79
London AIM United Kingdom (GB)
Top
News
4BASEBIO PLC - Investor Presentation
14 Jun 2022 - 06:49
Second Price Monitoring Extn
25 Feb 2021 - 09:05
Price Monitoring Extension
25 Feb 2021 - 09:00
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Show archived

NB! Information about past events and all documents are available for signed in users who have bought those events.

Type
Ticker
ISIN
Market
SHARE
4BB
GB00BMCLYF79
London AIM
United Kingdom (GB)
Details of share in 4basebio Plc with ticker 4BB
Status
Active
Currency
GBP
Segment
ASQ1
Listing
Sign in to buy
Type
Ticker
ISIN
Market
SHARE
4BB
GB00BLD8ZL39
London AIM
United Kingdom (GB)
Details of share in 4basebio Plc with ticker 4BB
Status
Archived
Currency
GBP
Segment
ASQ1
Listing
Sign in to buy
Type
Ticker
ISIN
Market
SHARE
4BB
GB00BMCLYF79
London AIM
United Kingdom (GB)
Details of share in 4basebio Plc with ticker 4BB
Status
Active
Currency
GBP
Segment
ASQ1
People
Heikki Lanckriet
CEO
Timothy Paul McCarthy
Chairman of the board
David John Roth
Board member
Hansjörg Plaggemars
Board member
Joseph Manuel Fernández
Board member
Maria del Pilar de la Huerta Martinez
Board member
Company Details
Sector
HEALTH CARE
Website
Address
25 Norman Way
Zip code
CB24 5QE
City/district
Cambridge
Country
United Kingdom (GB)
Phones
Email
[email protected]
Registration number
13519889
LEI code
2138005D5SAG8FIR6G91
First trade date
17 Feb 2021
Company former names
4basebio UK Societas
28 Jul 2021
Registration date
05 Nov 2019
Short name
4BB

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More